Cinctive Capital Management’s AstraZeneca AZN Stock Holding History

Cinctive Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Sell	5,802 -25,169	-81%	-$4.73M	0.04%	318
2026 Q1	$6.11M	Buy	30,971 +28,931	+1,418%	+$5.58M	0.4%	88
2025 Q4	$375K	Sell	2,040 -59,221	-97%	-$10.4M	0.02%	344
2025 Q3	$9.4M	Buy	61,261 +40,274	+192%	+$6.1M	0.45%	62
2025 Q2	$2.93M	Sell	20,987 -23,236	-53%	-$3.26M	0.16%	176
2025 Q1	$6.5M	Buy	44,223 +1,896	+4%	+$274K	0.5%	62
2024 Q4	$5.55M	Buy	42,327 +19,859	+88%	+$2.78M	0.28%	120
2024 Q3	$3.5M	Buy	+22,468	New	+$3.63M	0.19%	175
2024 Q1	–	Sell	-9,029	Closed	-$1.22M	–	395
2023 Q4	$1.22M	Buy	+9,029	New	+$1.17M	0.08%	235
2022 Q3	–	Sell	-33,119	Closed	-$4.38M	–	471
2022 Q2	$4.38M	Sell	33,119 -15,736	-32%	-$2.06M	0.18%	181
2022 Q1	$6.48M	Buy	48,855 +16,455	+51%	+$1.97M	0.24%	142
2021 Q4	$3.77M	Buy	32,400 +17,400	+116%	+$2.05M	0.17%	204
2021 Q3	$1.8M	Buy	+15,000	New	+$1.75M	0.09%	318

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cinctive Capital Management's AZN Position: Q2 2026 in Review

Cinctive Capital Management reduced its AstraZeneca (AZN) stake by 81% in Q2 2026, selling an estimated $4.73M and leaving 5,802 shares worth $1.1M. The position accounts for 0.04% of the portfolio, ranked #318.

Cinctive Capital Management first reported a position in AZN in Q3 2021 and has held it in 13 quarters since. The position peaked at $9.4M in Q3 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cinctive Capital Management held 5,802 shares of AstraZeneca worth $1.1M as of Q2 2026.
Cinctive Capital Management sold 25,169 AstraZeneca shares in Q2 2026, an estimated $4.73M.
AstraZeneca made up 0.04% of Cinctive Capital Management's portfolio in Q2 2026, its #318 holding.
Cinctive Capital Management first reported a position in AstraZeneca in Q3 2021 and has held it in 13 quarters since.
Cinctive Capital Management's AstraZeneca position peaked at $9.4M in Q3 2025.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.